Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Sodium Alginate Oral Suspension in GERD
NCT02623062Phase 3Completed
- Sponsor
- Reckitt
- Start
- Dec 2013
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of magnesium trisilicate in gastroesophageal reflux disease (GERD), sponsored by Reckitt. Started Dec 2013; status: completed.
02
Drugs
magnesium trisilicate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02623062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623062.